- LXRP files for patent with the USPTO for DehydraTECH’s innovative treatment options for diseases and disorders including Alzheimer’s, Huntington’s and Parkinson’s
- Company hopes to leverage this future possible patent to commercialize its development or out-licensing of future new products that treat central nervous system diseases
- DehydraTECH platform, being lab tested for drug delivery, effectively transported nicotine across the blood brain barrier, a barrier that protects the brain and makes traditional treatment difficult
Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) patented DehydraTECH™ drug delivery platform has already received some eight patents granted and nearly 50 pending worldwide, and the company has applied for one more to the USPTO. This is because, in lab studies, the proprietary technology has shown evidence of transporting active pharmaceutical ingredients (APIs) across the brain’s protective blood brain barrier, the company announced in an article published by the CFN Media Group (http://cnw.fm/Ze5gE).
That barrier blocks blood borne circulating toxins and is a challenge to researchers trying to deliver APIs in medications past it. The barrier serves as a significant hindrance for drug treatment of diseases of the central nervous system. DehydraTECH technology, in animal lab tests, was able to transport more nicotine to the brain tissue, conjugating or joining with APIs for maximum delivery.
Based in British Columbia, Canada, LXRP is a biotechnology company that out-licenses its disruptive delivery technology that promotes healthier ingestion methods. It results in lower dosing and higher effectiveness. LXRP holds a patent for oral delivery of all cannabinoids. It has a growing IP portfolio and will license in any of the 40 countries worldwide where its technology already has a patent or is patent-pending. DehydraTECH is its proprietary delivery technology platform.
LXRP has conducted in vivo lab studies on animals to, in part, determine DehydraTECH’s ability to deliver enhanced levels of nicotine to the bloodstream and brain tissue. The studies found that this platform was able to deliver up to 560 percent greater amounts of nicotine to the brain tissue compared to controls without DehydraTECH.
Originally, the tests were focused on developing products for nicotine replacement by LXRP (http://cnw.fm/nNi1Z), which is itself a multi-billion market with profound need for more effective alternatives. However, the tests demonstrated that DehydraTECH could effectively transport drugs, in this case nicotine, across the blood brain barrier. The diseases affected include Alzheimer’s, Parkinson’s, Huntington’s, schizophrenia, depression, anxiety and neuropathic pain. The versatility of Lexaria’s DehydraTECH™ drug delivery platform is apparent, and its limitations are not yet known.
For more information, visit the company’s website at www.LexariaBioscience.com
More from CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CannabisNewsWire.com